BR112014011981B8 - Formulações farmacêuticas sólidas orais, seus processos de preparação e usos - Google Patents

Formulações farmacêuticas sólidas orais, seus processos de preparação e usos

Info

Publication number
BR112014011981B8
BR112014011981B8 BR112014011981A BR112014011981A BR112014011981B8 BR 112014011981 B8 BR112014011981 B8 BR 112014011981B8 BR 112014011981 A BR112014011981 A BR 112014011981A BR 112014011981 A BR112014011981 A BR 112014011981A BR 112014011981 B8 BR112014011981 B8 BR 112014011981B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulations
solid pharmaceutical
oral solid
preparation processes
solid
Prior art date
Application number
BR112014011981A
Other languages
English (en)
Other versions
BR112014011981A2 (pt
BR112014011981A8 (pt
BR112014011981B1 (pt
Inventor
Verma Daya
Krishnamachari Yogita
Shen Xiaohong
Lee Hanchen
Li Ping
Singh Rajinder
Tan Laychoo
Original Assignee
Novartis Ag
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47501412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014011981(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Array Biopharma Inc filed Critical Novartis Ag
Publication of BR112014011981A2 publication Critical patent/BR112014011981A2/pt
Publication of BR112014011981A8 publication Critical patent/BR112014011981A8/pt
Publication of BR112014011981B1 publication Critical patent/BR112014011981B1/pt
Publication of BR112014011981B8 publication Critical patent/BR112014011981B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAÇÕES FARMACÊUTICAS SÓLIDAS ORAIS E SEUS USOS. A presente invenção refere-se a formulações farmacêuticas orais sólidas de (1-((4-(3-(5-cloro-2-fluoro-3-(metilsulfonamido)fenil)-1-isopropil-1H-pirazol-4-il)pirimidin-2-il)amino)propan-2-il)carbamato de (S)-metila (COMPOSTO A). A invenção refere-se ainda ao uso das referidas formulações farmacêuticas na preparação de medicamentos para o tratamento de uma doença proliferativa, tais como as doenças de tumores sólidos.
BR112014011981A 2011-11-23 2012-11-21 Formulações farmacêuticas sólidas orais, seus processos de preparação e usos BR112014011981B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161563229P 2011-11-23 2011-11-23
US61/563,229 2011-11-23
PCT/US2012/066185 WO2013078264A1 (en) 2011-11-23 2012-11-21 Pharmaceutical formulations

Publications (4)

Publication Number Publication Date
BR112014011981A2 BR112014011981A2 (pt) 2017-05-30
BR112014011981A8 BR112014011981A8 (pt) 2018-07-31
BR112014011981B1 BR112014011981B1 (pt) 2020-11-17
BR112014011981B8 true BR112014011981B8 (pt) 2022-07-19

Family

ID=47501412

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014011981A BR112014011981B8 (pt) 2011-11-23 2012-11-21 Formulações farmacêuticas sólidas orais, seus processos de preparação e usos

Country Status (38)

Country Link
US (4) US9387208B2 (pt)
EP (2) EP2782557B1 (pt)
JP (2) JP6216325B2 (pt)
KR (1) KR102091295B1 (pt)
CN (2) CN105708819B (pt)
AR (1) AR088936A1 (pt)
AU (1) AU2012340759C1 (pt)
BR (1) BR112014011981B8 (pt)
CA (1) CA2856406C (pt)
CL (1) CL2014001337A1 (pt)
CO (1) CO6940426A2 (pt)
CY (1) CY1121421T1 (pt)
DK (1) DK2782557T3 (pt)
EA (1) EA025389B1 (pt)
EC (1) ECSP23034537A (pt)
ES (1) ES2695099T3 (pt)
GT (1) GT201400100A (pt)
HK (1) HK1197024A1 (pt)
HR (1) HRP20181896T1 (pt)
HU (1) HUE040370T2 (pt)
IL (1) IL232305B (pt)
JO (1) JO3493B1 (pt)
LT (1) LT2782557T (pt)
MA (1) MA35716B1 (pt)
MX (1) MX353446B (pt)
MY (1) MY172729A (pt)
PE (1) PE20141994A1 (pt)
PH (1) PH12014501157B1 (pt)
PL (1) PL2782557T3 (pt)
PT (1) PT2782557T (pt)
RS (1) RS58048B1 (pt)
SG (1) SG11201401260QA (pt)
SI (1) SI2782557T1 (pt)
TN (1) TN2014000145A1 (pt)
TW (1) TWI649098B (pt)
UA (1) UA115039C2 (pt)
WO (1) WO2013078264A1 (pt)
ZA (1) ZA201402418B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2776037B1 (en) 2011-11-11 2019-01-09 Novartis AG Method of treating a proliferative disease
JP6216325B2 (ja) 2011-11-23 2017-10-18 ノバルティス アーゲー 医薬製剤
KR102369405B1 (ko) 2015-06-04 2022-03-02 화이자 인코포레이티드 팔보시클립의 고체 투여 형태
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
HUE060653T2 (hu) 2016-06-03 2023-04-28 Array Biopharma Inc Gyógyászati kombinációk
CN106000220A (zh) * 2016-06-30 2016-10-12 东华大学 一种含化学试剂的有机溶剂崩解片的制备方法与应用
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
AU2021358394A1 (en) 2020-10-05 2023-04-13 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma
CN114557977A (zh) * 2022-02-16 2022-05-31 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
WO2023239337A1 (en) * 2022-06-08 2023-12-14 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi A pharmaceutical composition comprising palbociclib

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
CA2231050A1 (en) 1995-09-07 1997-03-13 Biovail International Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
WO1998052940A1 (en) 1997-05-22 1998-11-26 G.D. Searle And Co. SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
ES2398643T3 (es) 1999-12-23 2013-03-20 Mayne Pharma International Pty Ltd. Composiciones farmacéuticas mejoradas para fármacos escasamente solubles
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
DE60222804T2 (de) 2001-12-21 2008-07-03 Vernalis (Cambridge) Ltd., Abington 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
AU2002350719A1 (en) * 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
BRPI0506760A (pt) 2004-01-09 2007-05-22 Novartis Ag derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inibidores de igf-ir
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
CA2618377A1 (en) 2005-08-12 2007-02-22 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate hsp90 activity
MX2008002492A (es) * 2005-08-22 2008-04-03 Novartis Ag Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
CA2643066A1 (en) 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
WO2007123892A2 (en) 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
JP5153777B2 (ja) 2006-10-02 2013-02-27 アイアールエム・リミテッド・ライアビリティ・カンパニー タンパク質キナーゼとしての化合物および組成物
CN101522026A (zh) 2006-10-06 2009-09-02 Irm责任有限公司 蛋白激酶抑制剂及其应用方法
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
KR20100038119A (ko) 2007-08-01 2010-04-12 화이자 인코포레이티드 피라졸 화합물 및 ｒａｆ 억제제로서 이의 용도
CA2699301A1 (en) * 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product of n-aryl urea-based drugs
CN101861316B (zh) 2007-11-14 2013-08-21 奥梅-杨森制药有限公司 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
WO2009115572A2 (en) 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
MX2011000738A (es) 2008-07-24 2011-02-23 Nerviano Medical Sciences Srl 3,4-diarilpirazoles como inhibidoers de proteina cinasa.
BRPI0916713A2 (pt) 2008-07-28 2015-11-10 Gilead Science Inc compostos inibidores de histona desacetilase de cicloalquilideno e heterocicloalquilideno
WO2010034838A2 (en) 2008-09-29 2010-04-01 Boehringer Ingelheim International Gmbh New chemical compounds
BRPI0920604B1 (pt) * 2008-10-07 2021-11-23 Kudos Pharmaceuticals Limited Formulação farmacêutica de liberação imediata na forma de uma dispersão sólida compreendendo como ativo o composto 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-flúor- benzil]-2h-ftalazin-1-ona (olaparibe)
US20110293750A1 (en) 2008-11-11 2011-12-01 Yale University Activated wnt-beta-catenin signaling in melanoma
JP5490137B2 (ja) 2008-12-19 2014-05-14 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ プロテインキナーゼ阻害薬としての二環式ピラゾール
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) * 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
US8546413B2 (en) 2009-06-15 2013-10-01 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2528909B1 (en) 2010-01-27 2016-06-22 Nerviano Medical Sciences S.r.l. Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
CN103153980B (zh) 2010-08-03 2015-12-16 内尔维安诺医学科学有限公司 吡唑并苯基苯磺酰胺化合物的衍生物及其作为抗肿瘤药的用途
WO2012128709A1 (en) 2011-03-21 2012-09-27 Valcuria Ab A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof.
BR112013032125A2 (pt) 2011-06-14 2016-12-13 Novartis Ag combinação de panobinostat e ruxolitinibe no tratamento de câncer do tipo neoplasia mieloproliferativa
JP6216325B2 (ja) 2011-11-23 2017-10-18 ノバルティス アーゲー 医薬製剤
RU2015121367A (ru) 2012-11-08 2017-01-10 Новартис Аг Фармацевтическая комбинация, содержащая ингибитор b-raf и ингибитор деацетилазы гистонов, и ее применение при лечении пролиферативных заболеваний

Also Published As

Publication number Publication date
US20160279129A1 (en) 2016-09-29
WO2013078264A1 (en) 2013-05-30
PE20141994A1 (es) 2014-12-24
GT201400100A (es) 2017-09-28
EP2782557B1 (en) 2018-09-12
EP3449911A1 (en) 2019-03-06
CL2014001337A1 (es) 2014-10-24
KR20140095500A (ko) 2014-08-01
IL232305B (en) 2019-06-30
PH12014501157A1 (en) 2014-08-11
EA025389B1 (ru) 2016-12-30
US10258622B2 (en) 2019-04-16
BR112014011981A2 (pt) 2017-05-30
BR112014011981A8 (pt) 2018-07-31
US20140309250A1 (en) 2014-10-16
RS58048B1 (sr) 2019-02-28
MY172729A (en) 2019-12-11
CA2856406A1 (en) 2013-05-30
JP6216325B2 (ja) 2017-10-18
HUE040370T2 (hu) 2019-03-28
SG11201401260QA (en) 2014-07-30
PH12014501157B1 (en) 2014-08-11
AU2012340759C1 (en) 2019-11-28
US20170202837A1 (en) 2017-07-20
US9763941B2 (en) 2017-09-19
JO3493B1 (ar) 2020-07-05
MA35716B1 (fr) 2014-12-01
US20190054086A1 (en) 2019-02-21
MX2014006278A (es) 2014-07-09
CO6940426A2 (es) 2014-05-09
EA201491007A1 (ru) 2014-08-29
BR112014011981B1 (pt) 2020-11-17
ECSP23034537A (es) 2023-08-31
NZ623628A (en) 2016-05-27
PT2782557T (pt) 2018-11-26
US9387208B2 (en) 2016-07-12
AU2012340759B2 (en) 2016-04-28
CN105708819A (zh) 2016-06-29
CA2856406C (en) 2020-06-23
DK2782557T3 (en) 2018-12-10
SI2782557T1 (sl) 2019-02-28
JP2015501808A (ja) 2015-01-19
UA115039C2 (uk) 2017-09-11
US10561654B2 (en) 2020-02-18
TW201328722A (zh) 2013-07-16
AR088936A1 (es) 2014-07-16
PL2782557T3 (pl) 2019-03-29
TWI649098B (zh) 2019-02-01
HK1197024A1 (en) 2015-01-02
CY1121421T1 (el) 2020-05-29
MX353446B (es) 2018-01-12
AU2012340759A1 (en) 2014-05-29
IL232305A0 (en) 2014-06-30
LT2782557T (lt) 2018-12-27
CN105708819B (zh) 2020-12-29
JP2018035171A (ja) 2018-03-08
HRP20181896T1 (hr) 2019-02-22
EP2782557A1 (en) 2014-10-01
ES2695099T3 (es) 2019-01-02
TN2014000145A1 (en) 2015-09-30
ZA201402418B (en) 2015-03-25
KR102091295B1 (ko) 2020-03-19
CN103945831A (zh) 2014-07-23

Similar Documents

Publication Publication Date Title
BR112014011981A8 (pt) Formulações farmacêuticas sólidas orais, seus processos de preparação e usos
CY1118813T1 (el) Φαρμακευτικες συνθεσεις συν-κρυσταλλων τραμαδολης και κοξιμπων
CL2014001792A1 (es) Compuestos derivados de carbamato; composicion farmaceutica, y uso de los mismos en el tratamiento del dolor, cancer por tumor solido, obesidad, entre otras enfermedades.
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
TN2011000263A1 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
CU20100216A7 (es) Polipéptidos derivados de la il-2 con actividad agonista y mayor eficacia para la terapia del cáncer e infecciones crónicas
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
BR112014015568A2 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
ES2446643R1 (es) Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular
EA201590562A1 (ru) Бензамиды
PH12015500823A1 (en) Modified release formulations for oprozomib
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
BR112015007592A2 (pt) composições de enalapril
WO2015048503A3 (en) N-arylmethyl sulfonamide negative modulators of nr2a
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
BR112016007031A2 (pt) composição farmacêutica oral sólida, processo para a preparação de uma composição farmacêutica, composição farmacêutica bicamada oral sólida, e uso de uma composição farmacêutica
UA112981C2 (uk) Варіант людського gdnf
EA201400786A1 (ru) Карбоциклические нуклеозиды, их фармацевтическое применение и композиции
CL2013000655A1 (es) Compuestos derivados de fenoxidihidrobenzoxatiazepinas, moduladores de receptores ampa; composicion farmaceutica; procedimiento para preparalos; compuestos intermediarios; y su uso para el tratamiento o prevencion de trastornos mnemocognitivos asociados a la edad, sindromes ansiosos o depresivos y alzheimer, entre otras enfermedades.
TR201105424A2 (tr) Çinko etken maddeli bir farmasötik formülasyon.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ARRAY BIOPHARMA, INC. (US)

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA A PETICAO NO 870180031808 DE 19/04/2018, COM BASE NO DISPOSTO NO ART. 219, II DA LEI DA PROPRIEDADE INDUSTRIAL, HAJA VISTA QUE O INTERESSADO NAO TEM LEGITIMIDADE PARA O ATO.

B150 Others concerning applications: publication cancelled [chapter 15.30 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 15.7 NA RPI NO 2508 DE 29/01/2019 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: A61K 9/14 , A61K 9/20 , A61K 9/48

Ipc: A61K 31/506 (2006.01), A61K 9/00 (2006.01), A61K 9

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/11/2012, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REFERENTE A RPI 2602 DE 17/11/2020, QUANTO AO ITEM (73) NOME DO TITULAR.